KEY SFBC MIAMI ASSETS ACQUIRED BY ALLIED RESEARCH INTERNATIONAL
Allied Research International (ARI), Canada's leading contract research organization (CRO), announced today that it has acquired key assets of South Florida Bioavailability Clinic International's (SFBC) Miami, Florida operations.
TORONTO – August 16, 2006 – Allied Research International (ARI), Canada's leading contract research organization (CRO), announced today that it has acquired key assets of South Florida Bioavailability Clinic International's (SFBC) Miami, Florida operations. The acquired assets include a fully-functional clinical laboratory and equipment, and a 46-station cardiac monitoring suite.
"These assets will be re-located to ARI's new state-of-the-art, 150-bed Phase 1 clinic in Miami that opened this spring. ARI will also employ selected leading staff from SFBC's Miami operations," said Dr. Piyush Patel MD, CEO and Founder of ARI.
ARI now has significantly expanded capacity to perform complex Phase 1 and special population studies in the Miami area, There is a large need for these types of studies and for which few other CROs specialize.
The expanded facilities in Miami add to ARI's 80-bed Phase 1 unit in Toronto, Canada, bringing its total capacity to over 230 Phase I beds.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
